Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05411380
Status:
RECRUITING
Last Update Posted:
2022-11-04
First Post:
2022-06-05
Brief Title:
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive HER2-negative Breast Cancer After CDK46 Inhibitor
Sponsor:
wang shusen
Organization:
Sun Yat-sen University
Organization Data
Organization:
Sun Yat-sen University
Class:
OTHER
Study ID:
SYSUCC-020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
wang shusen
Lead Sponsor Class:
OTHER
Responsible Party:
wang shusen
Responsible Party Title:
Chief Physician
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Sun Yat-sen University
Old Name:
None
Old Organization:
None